Age-related macular degeneration

CLINICAL QUESTION: Is there any new knowledge about the pathogenesis and treatment of age-related macular degeneration (AMD)? RESULTS: We now understand better the biochemical and pathological pathways involved in the genesis of AMD. Treatment of exudative AMD is based on intravitreal injection of n...

Descripción completa

Detalles Bibliográficos
Autores principales: Querques, Giuseppe, Avellis, Fernando Onofrio, Querques, Lea, Bandello, Francesco, Souied, Eric H
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Evidence 2 Practice
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102591/
https://www.ncbi.nlm.nih.gov/pubmed/21654887
http://dx.doi.org/10.2147/OPTH.S10161
_version_ 1782204389736316928
author Querques, Giuseppe
Avellis, Fernando Onofrio
Querques, Lea
Bandello, Francesco
Souied, Eric H
author_facet Querques, Giuseppe
Avellis, Fernando Onofrio
Querques, Lea
Bandello, Francesco
Souied, Eric H
author_sort Querques, Giuseppe
collection PubMed
description CLINICAL QUESTION: Is there any new knowledge about the pathogenesis and treatment of age-related macular degeneration (AMD)? RESULTS: We now understand better the biochemical and pathological pathways involved in the genesis of AMD. Treatment of exudative AMD is based on intravitreal injection of new antivascular endothelial growth factor drugs for which there does not yet exist a unique recognized strategy of administration. No therapies are actually available for atrophic AMD, despite some experimental new pharmacological approaches. IMPLEMENTATION: strategy of administration, safety of intravitreal injection
format Text
id pubmed-3102591
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-31025912011-06-07 Age-related macular degeneration Querques, Giuseppe Avellis, Fernando Onofrio Querques, Lea Bandello, Francesco Souied, Eric H Clin Ophthalmol Evidence 2 Practice CLINICAL QUESTION: Is there any new knowledge about the pathogenesis and treatment of age-related macular degeneration (AMD)? RESULTS: We now understand better the biochemical and pathological pathways involved in the genesis of AMD. Treatment of exudative AMD is based on intravitreal injection of new antivascular endothelial growth factor drugs for which there does not yet exist a unique recognized strategy of administration. No therapies are actually available for atrophic AMD, despite some experimental new pharmacological approaches. IMPLEMENTATION: strategy of administration, safety of intravitreal injection Dove Medical Press 2011 2011-05-18 /pmc/articles/PMC3102591/ /pubmed/21654887 http://dx.doi.org/10.2147/OPTH.S10161 Text en © 2011 Querques et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Evidence 2 Practice
Querques, Giuseppe
Avellis, Fernando Onofrio
Querques, Lea
Bandello, Francesco
Souied, Eric H
Age-related macular degeneration
title Age-related macular degeneration
title_full Age-related macular degeneration
title_fullStr Age-related macular degeneration
title_full_unstemmed Age-related macular degeneration
title_short Age-related macular degeneration
title_sort age-related macular degeneration
topic Evidence 2 Practice
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3102591/
https://www.ncbi.nlm.nih.gov/pubmed/21654887
http://dx.doi.org/10.2147/OPTH.S10161
work_keys_str_mv AT querquesgiuseppe agerelatedmaculardegeneration
AT avellisfernandoonofrio agerelatedmaculardegeneration
AT querqueslea agerelatedmaculardegeneration
AT bandellofrancesco agerelatedmaculardegeneration
AT souiederich agerelatedmaculardegeneration

Ejemplares similares